The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Hyaluronan-CD44 Interaction with Protein Kinase Cϵ Promotes Oncogenic Signaling by the Stem Cell Marker Nanog and the Production of MicroRNA-21, Leading to Down-regulation of the Tumor Suppressor Protein PDCD4, Anti-apoptosis, and Chemotherapy Resistance in Breast Tumor Cells
Open accessAbstract
Multidrug resistance and disease relapse is a challenging clinical problem in the treatment of breast cancer. In this study, we investigated the hyaluronan (HA)-induced interaction between CD44 (a primary HA receptor) and protein kinase Cepsilon (PKCepsilon), which regulates a number of human breast tumor cell functions. Our results indicate that HA binding to CD44 promotes PKCepsilon activation, which, in turn, increases the phosphorylation of the stem cell marker, Nanog, in the breast tumor cell line MCF-7. Phosphorylated Nanog is then translocated from the cytosol to the nucleus and becomes associated with RNase III DROSHA and the RNA helicase p68. This process leads to microRNA-21 (miR-21) production and a tumor suppressor protein (e.g. PDCD4 (program cell death 4)) reduction. All of these events contribute to up-regulation of inhibitors of apoptosis proteins (IAPs) and MDR1 (multidrug-resistant protein), resulting in anti-apoptosis and chemotherapy resistance. Transfection of MCF-7 cells with PKCepsilon or Nanog-specific small interfering RNAs effectively blocks HA-mediated PKCepsilon-Nanog signaling events, abrogates miR-21 production, and increases PDCD4 expression/eIF4A binding. Subsequently, this PKCepsilon-Nanog signaling inhibition causes IAP/MDR1 down-regulation, apoptosis, and chemosensitivity. To further evaluate the role of miR-21 in oncogenesis and chemoresistance, MCF-7 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and inhibit its target functions. Our results indicate that anti-miR-21 inhibitor not only enhances PDCD4 expression/eIF4A binding but also blocks HA-CD44-mediated tumor cell behaviors. Thus, this newly discovered HA-CD44 signaling pathway should provide important drug targets for sensitizing tumor cell apoptosis and overcoming chemotherapy resistance in breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
MicroRNA genes are transcribed by RNA polymerase II
Lee, Y., Kim, M., Han, J., Yeom, K., Lee, S., Baek, S. H., & Kim, V. N. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600385 · Cited by 4,373
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Functional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem Cells
Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S., & Smith, A. (2003) · Cell · doi:10.1016/s0092-8674(03)00392-1 · Cited by 3,255
The Homeoprotein Nanog Is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., Maeda, M., & Yamanaka, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00393-3 · Cited by 3,191
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
Cited by
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Zöller, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3023 · Cited by 1,112
Misra, S., Hascall, V. C., Markwald, R. R., & Ghatak, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00201 · Cited by 830
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Yan, Y., Zuo, X., & Wei, D. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0048 · Cited by 633
Hyaluronan: molecular size‐dependent signaling and biological functions in inflammation and cancer
Tavianatou, A. G., Caon, I., Franchi, M., Piperigkou, Z., Galesso, D., & Karamanos, N. K. (2019) · The FEBS Journal · doi:10.1111/febs.14777 · Cited by 462
Emerging role of microRNA-21 in cancer
Feng, Y.-H., & Tsao, C.-J. (2016) · Biomedical Reports · doi:10.3892/br.2016.747 · Cited by 454
Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma
Tomimaru, Y., Eguchi, H., Nagano, H., Wada, H., Kobayashi, S., Marubashi, S., Tanemura, M., Tomokuni, A., Takemasa, I., Umeshita, K., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.026 · Cited by 361
Wang, Z., Li, Y., Ahmad, A., Azmi, A. S., Kong, D., Banerjee, S., & Sarkar, F. H. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.07.001 · Cited by 343
Cancer stem cell in breast cancer therapeutic resistance
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.004 · Cited by 328
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., & Song, E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216887 · Cited by 311
Hyaluronan in human malignancies
Sironen, R. K., Tammi, M., Tammi, R., Auvinen, P. K., Anttila, M., & Kosma, V.-M. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.11.017 · Cited by 294
Bourguignon, L. Y. W., Wong, G., Earle, C., & Chen, L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308528 · Cited by 293
Self-citationHwang, J.-H., Voortman, J., Giovannetti, E., Steinberg, S. M., Leon, L. G., Kim, Y.-T., Funel, N., Park, J. K., Kim, M. A., Kang, G. H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010630 · Cited by 290
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Martin-Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I., & Ayala-San Nicolas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 286
The plasticity of mRNA translation during cancer progression and therapy resistance
Fabbri, L., Chakraborty, A., Robert, C., & Vagner, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00380-y · Cited by 276
Understanding the Dual Nature of CD44 in Breast Cancer Progression
Louderbough, J. M. V., & Schroeder, J. A. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0156 · Cited by 273
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme
Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., & Itinteang, T. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00021 · Cited by 258
Yu, Y., Kanwar, S. S., Patel, B. B., Oh, P.-S., Nautiyal, J., Sarkar, F. H., & Majumdar, A. P. N. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr246 · Cited by 258
Snodgrass, R. G., Huang, S., Choi, I.-W., Rutledge, J. C., & Hwang, D. H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300298 · Cited by 243
Bourguignon, L. Y. W., Earle, C., Wong, G., Spevak, C. C., & Krueger, K. (2012) · Oncogene · doi:10.1038/onc.2011.222 · Cited by 239
Self-citationmiR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2
Zhu, W., Zhu, D., Lu, S., Wang, T., Wang, J., Jiang, B., Shu, Y., & Liu, P. (2012) · Medical Oncology · doi:10.1007/s12032-010-9797-4 · Cited by 189
Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo
Gaur, A. B., Holbeck, S. L., Colburn, N. H., & Israel, M. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor033 · Cited by 180
MicroRNA and Target Protein Patterns Reveal Physiopathological Features of Glioma Subtypes
Lages, E., Guttin, A., El Atifi, M., Ramus, C., Ipas, H., Dupré, I., Rolland, D., Salon, C., Godfraind, C., deFraipont, F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020600 · Cited by 128
Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., & Vagner, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2362 · Cited by 105
Metadata
- Authors
- Bourguignon, L. Y. W., Spevak, C. C., Wong, G., Xia, W., & Gilad, E.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 284
- Issue
- 39
- Pages
- 26533-26546
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1983985456
- Cited by
- 316
- References
- 86
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.